Assessment of PD-L1 expression by IHC has emerged as an important predictive biomarker for patients with non-small cell lung cancer (NSCLC) [12, 13], urothelial carcinoma [34], and renal cell cancer [60]. Here, CD274 is linked to non-small cell lung carcinoma.